Integra LifeSciences Updates 2018 Outlook - Quick Facts

(RTTNews) - Integra LifeSciences Holdings Corp. (IART) raised the low end of its full-year 2018 total revenue guidance by $5 million to a new range of $1.475 billion to $1.490 billion. The company also raised the low end of its full-year 2018 GAAP earnings per share guidance range to $0.71 to $0.77, and adjusted earnings per share guidance range to $2.36 to $2.42, an increase of two cents. The company continues to expect full-year 2018 organic revenue growth to be approximately 5.0%, consistent with prior guidance.

For the second quarter of 2018, adjusted earnings per share was $0.60, an increase of 33.3% over the prior year's quarter. Total revenues were $366.2 million, reflecting an increase of 29.8% over the second quarter of 2017. Sales in the Codman Specialty Surgical segment increased 49.8% compared to the second quarter of 2017, driven by the Codman acquisition and strong performance in the Dural Access and Repair and Advanced Energy businesses. Total organic revenues increased 3.4% over the second quarter of 2017, excluding acquisitions, divestitures and the effect of currency exchange rates.